TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35137142

Group type: EXPERIMENTAL
Intervention: DHEAS level
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Midnight serum cortisol level
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Suppressed adrenocorticotropic hormone (≤2.2 pmol/L)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 24-hour urinary free cortisol
Number of subjects: 287
Study: 35137154

Group type: EXPERIMENTAL
Intervention: GII.2 norovirus inoculum (1.2 × 10^4 to 1.2 × 10^7 genome equivalent copies [GEC]; n = 38)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 44
Study: 35137228

Group type: EXPERIMENTAL
Intervention: ONC201 treatment
Number of subjects: 24
Study: 35137301

Group type: EXPERIMENTAL
Intervention: Post-discharge mortality within 30 days after discharge
Number of subjects: 7882

Group type: EXPERIMENTAL
Intervention: Risk factors for post-discharge mortality
Number of subjects: 7882

Group type: EXPERIMENTAL
Intervention: Risk score for prediction of post-discharge mortality
Number of subjects: 7882
Study: 35137481

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Buprenorphine (BUP)
Number of subjects: 101
Study: 35137627

Group type: EXPERIMENTAL
Intervention: Low-dose sublingual fentanyl
Number of subjects: 95
Study: 35137871

Group type: EXPERIMENTAL
Intervention: ELMOcpap system (CPAP via ELMO interface with oxygen and compressed air flow meters at 30 L/min each, PEEP valve, CPAP levels = 8-10 cmH2O)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ELMOcpap system (CPAP at 10 cmH2O, total gas flow of 56-60 L/min)
Number of subjects: 10
Study: 35138325

Group type: EXPERIMENTAL
Intervention: 3-D LVEF
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GLS
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GCS
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: hsTnI
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Sequential algorithm using 3-D LVEF, GLS, and GCS
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 2-D LVEF
Number of subjects: 136
Study: 35138442

Group type: EXPERIMENTAL
Intervention: Appropriate DOAC dosage
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Inappropriate DOAC dosage
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Underdosage
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Overdosage
Number of subjects: 253

Group type: COMPARATOR
Intervention: Survival comparison between underdosage and appropriate dosage
Number of subjects: 253
Study: 35138444

Group type: EXPERIMENTAL
Intervention: Quantitative classification and radiomics
Number of subjects: 123
Study: 35138474

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 107
Study: 35138529

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine 25 mg/m
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Afatinib monotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combination therapy (afatinib plus vinorelbine or paclitaxel)
Number of subjects: 87
Study: 35138562

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (150,000 IU)
Number of subjects: 34
Study: 35138670

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 2191

Group type: COMPARATOR
Intervention: Emergency Severity Index (ESI)
Number of subjects: 2191
Study: 35138678

Group type: EXPERIMENTAL
Intervention: PrEP initiation at first ANC visit
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: PrEP continuation after 1 month
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: PrEP continuation after 3 months
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Side effects reported at 1 month
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Odds of reporting side effects for women in first and second trimesters
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women reporting side effects
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with ≥1 previous pregnancy
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for postpartum women
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with HIV+ partners
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with high HIV risk perception
Number of subjects: 1201
Study: 35138919

Group type: EXPERIMENTAL
Intervention: Taselisib monotherapy
Number of subjects: 70
Study: 35139037

Group type: EXPERIMENTAL
Intervention: Pneumococcal colonization
Number of subjects: 0
Study: 35139119

Group type: EXPERIMENTAL
Intervention: Supportive and dignified maternity care (SDMC) intervention package including capacity-building of maternity teams and improvement of governance and accountability mechanisms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive and dignified maternity care (SDMC) intervention package.
Number of subjects: 0
Study: 35139264

Group type: EXPERIMENTAL
Intervention: Chronic post-surgical neuropathic pain (CPSNP) patients
Number of subjects: 241

Group type: COMPARATOR
Intervention: Non-CPSNP patients
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: CPSNP patients
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 241
Study: 35139856

Group type: EXPERIMENTAL
Intervention: PET/CT-based adaptive radiotherapy planning
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Consistent planning strategy
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Tumor volume change during chemoradiotherapy
Number of subjects: 347
Study: 35139860

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (omega-3 PUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35139888

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction (ADSVF) combined with microfat
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 10
Study: 35139911

Group type: EXPERIMENTAL
Intervention: Systematic electronic screening for substance use and mental health symptoms via secure messaging and clinic-based tablets, integrated into the electronic health record (EHR).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multiple methods of questionnaire completion (secure messaging and clinic-based tablets).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patient-provider relationship.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Barriers to screening (privacy and confidentiality concerns, potential burden from repeated screenings).
Number of subjects: 21
Study: 35140147

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CAD)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Prostate Imaging-Reporting and Data System V.2.1 (PI-RADS V.2.1)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Combination of PHI and MRI findings
Number of subjects: 420
Study: 35140164

Group type: EXPERIMENTAL
Intervention: Feelix Smart Stethoscope
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Automated algorithm for lung sound interpretation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Automated algorithm
Number of subjects: 1000
Study: 35140619

Group type: EXPERIMENTAL
Intervention: CMAB807, a new Denosumab biosimilar
Number of subjects: 0
Study: 35141162

Group type: EXPERIMENTAL
Intervention: GAD-M regimen (Gemcitabine, Peg-Asparaginase, Dexamethasone, Methotrexate) administered for 6 cycles
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GAD-M regimen with radiotherapy for stage I/II patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GAD-M regimen for stage III/IV patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GAD-M regimen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Plasma MTX concentration ratio at 12 to 24 hr during the first cycle
Number of subjects: 36
Study: 35141170

Group type: EXPERIMENTAL
Intervention: Prognostic model based on age, fever at admission, and haematological parameters
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Prognostic model applied during temporal-external validation
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Haematological parameters (lactate dehydrogenase, platelet count, C-reactive protein, creatinine)
Number of subjects: 577
Study: 35141572

Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal weight group (BMI 18.5-24.9)
Number of subjects: 61
Study: 35141873

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 2023

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: PulmoCare enteral formula
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Oxepa enteral formula
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 2023
Study: 35142618

Group type: EXPERIMENTAL
Intervention: Patient portal research recruitment invitation
Number of subjects: 4510

Group type: EXPERIMENTAL
Intervention: Opened patient portal invitation
Number of subjects: 4510

Group type: EXPERIMENTAL
Intervention: Patient portal invitation
Number of subjects: 4510

Group type: EXPERIMENTAL
Intervention: Opened research invitation
Number of subjects: 4510
Study: 35142658

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (ELB/GZR) for 8 weeks
Number of subjects: 30
Study: 35143011

Group type: EXPERIMENTAL
Intervention: ERAS adherence (highest adherence quartile, Q1)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Self-designated ERAS group
Number of subjects: 1419
Study: 35143750

Group type: EXPERIMENTAL
Intervention: Effective contraceptive method
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Knowledge about pregnancy-related risks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Knowledge about planning pregnancy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Knowledge of preconception HbA1c target
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Appropriate knowledge about pregnancy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Use of contraindicated contraceptive method
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: No contraceptive method despite recommendation
Number of subjects: 122
Study: 35143771

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive adolescents
Number of subjects: 24315
Study: 35144270

Group type: EXPERIMENTAL
Intervention: Normocephalic infants
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Developmentally delayed group
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Auditory abnormalities
Number of subjects: 219
Study: 35144482

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35144487

Group type: EXPERIMENTAL
Intervention: NASH score (predictive model)
Number of subjects: 918
Study: 35144521

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35144742

Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by the third UDMI
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by the fourth UDMI
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by ARC-2
Number of subjects: 4404

Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by SCAI
Number of subjects: 4404
Study: 35144789

Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA) with the Mobius device
Number of subjects: 47
Study: 35144802

Group type: EXPERIMENTAL
Intervention: Change in cerebrospinal fluid/plasma albumin ratio (CPAR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Plasma S100B
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Blood loss
Number of subjects: 103
Study: 35144847

Group type: EXPERIMENTAL
Intervention: MenACYW-TT conjugate vaccine co-administered with routine pediatric vaccines (DTaP-IPV/Hib, PCV7/PCV13, MMR, and varicella)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACYW-TT conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine pediatric vaccines
Number of subjects: 0
Study: 35144953

Group type: EXPERIMENTAL
Intervention: Intermittent TBS (iTBS) on left DLPFC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continuous TBS (cTBS) on right DLPFC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 4 weeks of daily iTBS treatment of left DLPFC
Number of subjects: 70
Study: 35144989

Group type: EXPERIMENTAL
Intervention: Add-on inhaled budesonide
Number of subjects: 0
Study: 35145218

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (3 infusions)
Number of subjects: 199
Study: 35145465

Group type: EXPERIMENTAL
Intervention: Intradialytic cognitive training combined with physical exercise for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HD care
Number of subjects: 0
Study: 35145478

Group type: EXPERIMENTAL
Intervention: ANGPTL8
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 551
Study: 35145638

Group type: EXPERIMENTAL
Intervention: Baseline pNGAL measurement
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: pNGAL
Number of subjects: 698
Study: 35146146

Group type: EXPERIMENTAL
Intervention: Distal RDN
Number of subjects: 55

Group type: COMPARATOR
Intervention: Main trunk RDN
Number of subjects: 55
Study: 35146939

Group type: EXPERIMENTAL
Intervention: Infusional gemcitabine (100 mg/m) with concurrent radiotherapy (50.4-54 Gy over 28 days)
Number of subjects: 40
Study: 35147501

Group type: EXPERIMENTAL
Intervention: Onduo virtual care program with telemedicine consultations and RT-CGM
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Onduo virtual care program
Number of subjects: 55
Study: 35147580

Group type: EXPERIMENTAL
Intervention: PrEP (Pre-Exposure Prophylaxis)
Number of subjects: 348
Study: 35147794

Group type: EXPERIMENTAL
Intervention: Attendees of the FICS annual meeting
Number of subjects: 520

Group type: COMPARATOR
Intervention: Matched controls (healthcare professionals who stayed in the ICU)
Number of subjects: 520
Study: 35148417

Group type: EXPERIMENTAL
Intervention: CD19/CD28ζ CAR T-cells
Number of subjects: 52
Study: 35148720

Group type: EXPERIMENTAL
Intervention: Targeted HIV-1 nucleic acid (NA) testing intervention
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard provider-initiated testing using rapid antibody tests
Number of subjects: 1500
Study: 35148734

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive surgery (RA-MIS)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Robot-assisted open surgery (RA-OS)
Number of subjects: 208
Study: 35148798

Group type: COMPARATOR
Intervention: Otago alone (Arm 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Otago + Gentle Yoga and Yogic Breathing (Arm 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Otago + Gentle Yoga and Yogic Breathing + Behavioral Activation (Arm 3)
Number of subjects: 30
Study: 35148892

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep/Propofol
Number of subjects: 0
Study: 35149207

Group type: EXPERIMENTAL
Intervention: Arterial stiffness (pulse wave velocity measures: carotid-femoral, femoral-foot, carotid-radial, augmentation index, brachial distensibility)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Arterial stiffness
Number of subjects: 388
Study: 35149587

Group type: EXPERIMENTAL
Intervention: Inhibition of G9a and EZH2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal cells)
Number of subjects: 0
Study: 35149591

Group type: EXPERIMENTAL
Intervention: VCN-01 administered intratumorally at doses up to 1×10,
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCN-01 combined with standard chemotherapy,
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCN-01,
Number of subjects: 0
Study: 35149627

Group type: EXPERIMENTAL
Intervention: Self-Care for Heart Failure Index v6.2
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sleep characteristics
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction of <45
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 195
Study: 35149641

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12 weeks
Number of subjects: 19
Study: 35149851

Group type: EXPERIMENTAL
Intervention: BeEAM (Bendamustine-EAM)
Number of subjects: 280

Group type: COMPARATOR
Intervention: R-BEAM
Number of subjects: 280
Study: 35149868

Group type: EXPERIMENTAL
Intervention: cMyC 0/1h-algorithm
Number of subjects: 1495
Study: 35149871

Group type: EXPERIMENTAL
Intervention: Microbiota maturity and diversity
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Individual taxa (Bifidobacterium and Enterobacteriaceae)
Number of subjects: 611
Study: 35150024

Group type: EXPERIMENTAL
Intervention: Risk-loving attitudes
Number of subjects: 675

Group type: COMPARATOR
Intervention: Risky behaviors and time preferences
Number of subjects: 675
Study: 35150293

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test at 10 µg/kg/min
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test at 5, 10, 15 µg/kg/min
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test
Number of subjects: 52
Study: 35150296

Group type: EXPERIMENTAL
Intervention: 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment
Number of subjects: 59
Study: 35150356

Group type: EXPERIMENTAL
Intervention: M3541 (50-300 mg administered on RT fraction days)
Number of subjects: 15
Study: 35150355

Group type: COMPARATOR
Intervention: Supine-baseline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Supine-final
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sequential postural recruitment maneuver
Number of subjects: 15
Study: 35150403

Group type: EXPERIMENTAL
Intervention: Digital lifestyle management tool
Number of subjects: 297
Study: 35151024

Group type: EXPERIMENTAL
Intervention: Community-led responses to opioid prescribing practices
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Healthcare provider education and prescription drug monitoring programs
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Safer opioid prescribing guidelines
Number of subjects: 388
Study: 35151176

Group type: EXPERIMENTAL
Intervention: 5-item odorant test (U-Smell-It™)
Number of subjects: 1320
Study: 35151262

Group type: EXPERIMENTAL
Intervention: 2-axis turntable based BPPV treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Regular testing for BPPV and treatment with appropriate liberation maneuvers
Number of subjects: 75
Study: 35151268

Group type: EXPERIMENTAL
Intervention: Diosmectite (3 g/sachet, 3 sachets/day)
Number of subjects: 35
Study: 35151310

Group type: EXPERIMENTAL
Intervention: PHARM-DC intervention
Number of subjects: 10
Study: 35151584

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV infusion every 3 weeks) plus Tazemetostat (800 mg orally BID on days 1 to 21)
Number of subjects: 43
Study: 35152218

Group type: EXPERIMENTAL
Intervention: Previous history of falls
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Abnormal posture
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cognitive decline and fluctuating cognition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recurrent falling
Number of subjects: 66
Study: 35152295

Group type: EXPERIMENTAL
Intervention: CMV viremia ≥ 1000 IU/mL in HEU children
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Each 1-log increase in CMV viral load in HEU children
Number of subjects: 1024

Group type: COMPARATOR
Intervention: CMV viremia in HIV-unexposed children
Number of subjects: 1024
Study: 35152857

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 0
Study: 35152886

Group type: EXPERIMENTAL
Intervention: Dezamizumab
Number of subjects: 7
Study: 35152897

Group type: EXPERIMENTAL
Intervention: Haptic rendering
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weight support
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training with haptic rendering
Number of subjects: 40

Group type: COMPARATOR
Intervention: Training with weight support
Number of subjects: 40

Group type: COMPARATOR
Intervention: Training modalities
Number of subjects: 40
Study: 35153091

Group type: EXPERIMENTAL
Intervention: Plant-derived PA83-FhCMB vaccine at doses of 12.5, 25, 50, or 100 µg with Alhydrogel®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant-derived PA83-FhCMB vaccine
Number of subjects: 0
Study: 35153096

Group type: EXPERIMENTAL
Intervention: MOTIVE tool (MI-based communication tool)
Number of subjects: 2504
Study: 35153154

Group type: EXPERIMENTAL
Intervention: MR-guided radiation therapy (RT)
Number of subjects: 10
Study: 35153205

Group type: EXPERIMENTAL
Intervention: Violence exposure
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Cumulative effect of asthma morbidity
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Baseline violence exposure and depressive symptoms
Number of subjects: 276
Study: 35153967

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Impairment index (2 or more tests >1.5 SD below normative mean)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intraindividual variability in cognitive functioning
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brain injury symptom load
Number of subjects: 52
Study: 35154096

Group type: EXPERIMENTAL
Intervention: Preemptive interferon-α (IFN-α) therapy
Number of subjects: 9
Study: 35154388

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study: 35154389

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 103